1. Pink Sheet

Pending Approvals Hold Major Implications For Myozyme Growth

Genzyme reports increasing sales for Pompe disease drug, but upcoming EU and FDA decisions could spur or stifle product’s growth.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet